Trimurthi , a manufacturer and trader of active pharmaceutical ingredients, has announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company's Board of Directors approved these results at a meeting held on November 13, 2025.

Financial Highlights

• Revenue: The company reported a total income of Rs 3,639.14 crore for Q2 FY2026, compared to Rs 387.37 crore in the corresponding quarter of the previous year, marking a significant year-on-year growth.
• Net Profit: Trimurthi posted a net profit of Rs 52.47 crore for the quarter, showcasing a substantial increase from Rs 12.95 crore in Q2 FY2025.
• Half-Year Performance: For the half-year ended September 30, 2025, the company's total income stood at Rs 5,874.26 crore, with a net profit of Rs 64.03 crore.

Key Financial Metrics

Business Segment Performance

Trimurthi operates primarily in the pharmaceutical segment, focusing on the manufacture and trade of active pharmaceutical ingredients (bulk drugs). The company's financial results reflect its performance in this single business segment.

Balance Sheet Highlights

As of September 30, 2025, Trimurthi reported:

• Total Assets: Rs 7,180.33 crore
• Total Equity: Rs 2,560.96 crore
• Current Assets: Rs 7,061.96 crore, including inventories of Rs 305.64 crore

Corporate Governance Update

The company announced the resignation of Ms. Monam Kapoor from her position as an Independent Non-Executive Director, effective November 13, 2025. Ms. Kapoor cited pre-occupation and other personal commitments as reasons for her departure.

Trimurthi continues to adapt to market dynamics and regulatory requirements, as evidenced by its compliance with SEBI regulations and the timely filing of its quarterly results.

Investors and stakeholders are encouraged to review the detailed financial statements available on the company's website for a comprehensive understanding of Trimurthi's financial position and performance.

Trimurthi , a pharmaceutical company, has made significant corporate decisions that may interest investors and market watchers. The company's Board of Directors approved two key actions on October 23, 2025, as disclosed in their recent filing.

Board Appointment

The company has appointed Ms. Sridevi Belide as an Additional Non-Executive Non-Independent Director. Ms. Belide, who holds an MBBS degree, brings her medical expertise to the board. She is related to the company's promoter group.

Equity Share Allotment

The Board approved the allotment of 16,61,000 equity shares. Here are the key details of this allotment:

This allotment was made through the conversion of warrants, which were part of a larger issue of 1,50,00,000 warrants allotted on January 10, 2025. It's important to note that 45,30,000 warrants had already been converted prior to this allotment.

Impact on Share Capital

The equity share allotment has led to changes in the company's paid-up capital:

This increase in paid-up capital and the number of outstanding shares may have implications for the company's equity structure and potentially its market valuation.

Investors and market participants may want to consider how these corporate actions might affect Trimurthi's governance, capital structure, and future strategic directions.